Drug intelligence / Profile preview

New target D antibody

Development stage: Preclinical
Lead developer: Antibody Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

New target D antibody is an investigational monoclonal antibody developed by Antibody Therapeutics, currently in the preclinical stage of development. It is designed to target a novel, proprietary immuno-oncology target, designated as 'Target D', for the treatment of colon cancer. The candidate was discovered using the company's Computer Aided Antibody Discovery (CAAD) platform, which integrates computational tools to optimize antibody binding and therapeutic potential. As an immuno-oncology agent, it is intended to modulate the immune system's response to malignant cells in the colon.

Other names: Antibody Therapeutics-D

Targets

VISTA

Beyond the preview

Go deeper on New target D antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New target D antibody.

Explore the full profile